צרפת נגיף קורונה מטפלים בחולים שטרסבורג
Medics treating a coronavirus victim in France
Photo: Reuters
Medics treating a coronavirus victim in France

FDA approves Israeli drug for coronavirus treatment trials

Researchers are hoping that Aviptadil will be able to take on the so-called Acute Respiratory Distress Syndrome (ARDS) -- a condition responsible for about 50% of COVID-19 fatalities

i24NEWS |
Published: 03.31.20 , 09:01
The U.S. Food and Drug Administration on Sunday has cleared NeuroRx, a US-Israeli pharmaceutical company, and Relief Therapeutics, a Swiss drug development company, for phase two trials for a drug that could take on a deadly condition associated with COVID-19.

  • Follow Ynetnews on Facebook and Twitter

  • The two companies announced that the FDA issued a "study may proceed" letter -- which does not amount to a full-fledged drug approval -- for the substance to be tried on COVID-19 patients.
    צרפת נגיף קורונה מטפלים בחולים שטרסבורגצרפת נגיף קורונה מטפלים בחולים שטרסבורג
    Medics treating a coronavirus victim in France
    (Photo: Reuters)
    The drug in question, Aviptadil, is a synthetic form of a neuropeptide hormone that works to enable communications between neurons in the human nervous system.
    The researchers are hoping that Aviptadil will be able to take on the so-called Acute Respiratory Distress Syndrome (ARDS) -- a condition responsible for about 50% of COVID-19 fatalities.

    צרפת נגיף קורונה חולים ליד פריזצרפת נגיף קורונה חולים ליד פריז
    Coronavirus patient outside Paris hospital
    (Photo: Reuters)
    ARDS is a respiratory system failure induced by a rapid and severe lung inflammation, with breath shortness -- a symptom COVID-19 is widely associated with -- among its key signs.
    It effectively brings to a halt the oxygen and carbon dioxide exchange in the patient's lungs, necessitating the use of an artificial lung ventilation machine.

    Talkbacks for this article 0